Pregabalin Capsule
Product Images NDC 82804-207

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 82804-207). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-207-60 (Image 01)

Label for Pregabalin 75 mg capsules, bottle count 60, manufactured by MSN Laboratories Private Limited, India, and packaged by Proficient Rx LP. The label includes the NDC 82804-207-60, RX only status with controlled substance schedule C-V markings, and a description of the capsule appearance as white to off-white granular powder in size 4 hard gelatin capsules with a white opaque body imprinted 'PGBN' and light blue opaque cap imprinted '75'.*

FDA Label Image

Equation (Pregabain Gault Equation)

A mathematical formula for estimating creatinine clearance (CLCr), which adjusts for patient age, weight, serum creatinine level, and includes a multiplication factor for female patients. This text is a clinical calculation reference, not specific to the product Pregabalin itself.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. Four lines represent Pregabalin dosages of 200 mg, 100 mg, 25 mg three times a day, and placebo, displaying comparative patient improvement trends across different pain relief percentages.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A Kaplan-Meier curve chart showing the percent of patients improved relative to percent improvement in pain from baseline. Two groups are compared: Pregabalin 100 mg three times a day (dashed line) and placebo (dotted line). The y-axis represents the percent of patients improved, ranging from 0 to 100%, and the x-axis shows percent improvement in pain from baseline, ranging from >0% to 100%.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A graph depicting the percent of patients improved versus percent improvement in pain from baseline comparing Pregabalin dosages of 75 mg, 150 mg, and 300 mg taken two times a day, alongside a placebo group. The chart shows different curves for each dosage and placebo, illustrating the effect on pain improvement over varying percent thresholds.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A cumulative distribution plot comparing percent improvement in pain from baseline versus percent of patients improved. The graph shows three curves representing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The y-axis shows percent of patients improved and the x-axis shows percent improvement in pain from baseline, with vertical lines marking approximately 30% and 50% improvement thresholds.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line graph showing the percent of patients improved across different percent improvement levels in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line). The graph illustrates higher patient improvement percentages for Pregabalin groups compared to placebo as percent improvement increases from greater than 0 to 100.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

A bar chart showing responder rates (%) in two studies (E1 and E3) for different dosages and regimens compared to placebo. Study E1 bars range from 14% to 51% responder rates for placebo and 50mg to 600mg per day doses taken twice daily (BID). Study E3 shows placebo, 600mg BID, and 600mg three times daily (TID) with responder rates from 9% to 49%. Sample sizes (N) for each group are included below the bars.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

Line graph depicting seizure reduction in median percentage change from baseline versus dose of pregabalin (mg/day). Four different dosing regimens from Stukly studies (E1BID, E2BID, E3BID, E3TID) are represented by different symbols, showing increasing seizure reduction with higher doses up to 600 mg/day. Statistically significant p-values are noted at various dose points.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A Kaplan-Meier-type curve chart showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups receiving Pregabalin at daily doses of 600 mg, 450 mg, 300 mg, and a placebo, with improvement curves displayed as solid, dashed, and dotted lines respectively.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve chart depicting the estimated percentage of subjects without LTR (likely 'loss to remission') over a period of 180 days. The chart compares two groups: one receiving Pregabalin and the other receiving a placebo. The vertical axis represents the estimated percentage of subjects without LTR (0% to 100%), and the horizontal axis represents time in days (0 to 180). The solid line indicates the Pregabalin group, while the dashed line indicates the placebo group.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percent of subjects improved over a range of improvement percentages from baseline to week 12. The graph displays two lines: one solid line representing Pregabalin and one dashed line representing placebo. The y-axis shows the percent of subjects improved, while the x-axis shows the percent improvement from baseline. Pregabalin generally shows a higher percentage of subjects improved across the improvement range compared to placebo.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A line graph comparing the percentage of subjects improved over time from baseline to Week 16 for Pregabalin capsules 75 mg and placebo. The y-axis represents the percent of subjects improved, ranging from 0 to 100%, while the x-axis indicates the percent improvement from baseline to Week 16. The graph shows two lines: a solid line for Pregabalin and a dashed line for placebo, illustrating greater improvement in the Pregabalin group.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure of pregabalin showing its molecular framework with labeled functional groups, including an amino group, carboxylic acid, and hydrocarbon side chains.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.